Autopsy report · NCT02115035

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

“Funding issues”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

University of Arkansas

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Vermurafenib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• IRIS-BioFreedom Cohort in the IRIS-DES Registry
  “Funding issue” (93% match in meaning)
• Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars
  “technical and funding issues” (85% match in meaning)
• Cannabinoids for Taxane Induced Peripheral Neuropathy
  “Funding being sought” (81% match in meaning)
• Pilot Study of the Sage Guard for Oral Cavity Protection
  “Funding constraints” (81% match in meaning)
• Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
  “Inadequate funding” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.